Stage-specific immune dysregulation in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 34, Issue 8, 2014, Pages 633-640

  Segal, Benjamin M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; DISEASE MODIFYING AGENT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; MYELIN PROTEIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; PHARMACOLOGICAL BIOMARKER;

ADAPTIVE IMMUNITY; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPH FOLLICLE; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; ANIMAL; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; METABOLISM; MICROGLIA; PATHOLOGY; RECURRENT DISEASE; TH1 CELL; TH17 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; BIOMARKERS, PHARMACOLOGICAL; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICROGLIA; MULTIPLE SCLEROSIS; RECURRENCE; TH1 CELLS; TH17 CELLS;

EID: 84905383600     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0025     Document Type: Review

References (72)

1. Adams CW, Poston RN, Buk SJ. 1989. Pathology, histochem-istry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 92:291-306.
2. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, and others. 2013. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler 19:1204-1208.
3. Arbour N, Holz A, Sipe JC, Naniche D, Romine JS, Zyroff J, and others. 2003. A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J Neuroimmunol 137:197-209.
4. Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, and others. 2013. Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. Clin Immunol 147:105-119.
5. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. 1999. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 45: 247-250.
6. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, and others. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175.
7. Bielekova B, Komori M, Xu Q, Reich DS, Wu T. 2012. Cer-ebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 7:e48370.
8. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. 2004. Expansion and functional relevance of high-avidity myelin-specific CD4 + T cells in multiple sclerosis. J Immunol 172:3893-3904.
9. Calabresi PA, Fields NS, Farnon EC, Frank JA, Bash CN, Kawanashi T, and others. 1998. ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J Neuroimmunol 85:212-219.
10. Christensen JR, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, and others. 2013. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17-and activated B-cells and correlates with progression. PLoS One 8:e57820.
11. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, and others. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415.
12. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, and others. 2012. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829-1839.
13. Correale J, Gilmore W, McMillan M, Li S, McCarthy K, Le T, and others. 1995. Patterns of cytokine secretion by auto-reactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 154:2959-2968.
14. Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, and others. 2013. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 73:341-354.
15. de Graaf WL, Zwanenburg JJ, Visser F, Wattjes MP, Pouwels PJ, Geurts JJ, and others. 2012. Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. Eur Radiol 22:221-231.
16. de Rosbo NK, Ben-Nun A. 1998. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycopro-tein. J Autoimmun 11:287-299.
17. Dhib-Jalbut S, Sumandeep S, Valenzuela R, Ito K, Patel P, Rametta M. 2013. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. J Neuroimmunol 254:131-140.
18. Diaz-Villoslada P, Shih A, Shao L, Genain CP, Hauser SL. 1999. Autoreactivity to myelin antigens: myelin/oligodendro-cyte glycoprotein is a prevalent autoantigen. J Neuroimmunol 99:36-43.
19. Fallis RJ, Raine CS, McFarlin DE. 1989. Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope-specific T cell line. J Neuroimmunol 22:93-105.
20. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, and others. 2009. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler 15:1271-1279.
21. Filion LG, Matusevicius D, Graziani-Bowering GM, Kumar A, Freedman MS. 2003. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 106:127-138.
22. Filippi M, Rossi P, Campi A, Colombo B, Pereira C, Comi G. 1997. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. AJNR Am J Neu-roradiol 18:1549-1556.
23. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, and others. 2009. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-1189.
24. Gironi M, Saresella M, Rovaris M, Vaghi M, Nemni R, Clerici M, and others. 2013. A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. Immun Ageing 10:1.
25. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, and others. 2013. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 381:2167-2175.
26. Grau-López L, Raïch D, Ramo-Tello C, Naranjo-Gómez M, Dàvalos A, Pujol-Borrell R, and others. 2009. Myelin pep-tides in multiple sclerosis. Autoimmun Rev 8:650-653.
27. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. 2008. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125:161-169.
28. Hellings N, Barée M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, and others. 2001. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 63:290-302.
29. Hellings N, Gelin G, Medaer R, Bruckers L, Palmers Y, Raus J, and others. 2002. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. J Neuroimmunol 126: 143-160.
30. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, and others. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12:255-263.
31. Iwakura Y, Ishigame H, Saijo S, Nakae S. 2011. Functional specialization of interleukin-17 family members. Immunity 34:149-162.
32. Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, and others. 2006. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 177:4196-4202.
33. Karni A, Koldzic DN, Bharanidharan P, Khoury SJ, Weiner HL. 2002. IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+ ) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 125: 134-140.
34. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, and others. 2009. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 66:390-402.
35. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, and others. 2011. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 17:335-343.
36. Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, and others. 2011. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76:1214-1221.
37. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. 2008. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205:1535-1541.
38. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, and others. 2006. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200-211.
39. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, and others. 2005. Cortical de-myelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-2712.
40. Kvarnström M, Ydrefors J, Ekerfelt C, Vrethem M, Ernerudh J. 2013. Longitudinal interferon-b effects in multiple sclerosis: differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-g, IL-4 or IL-13. J Neurol Sci 325: 79-85.
41. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, and others. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
42. Lassmann H. 2010. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol 225:2-8.
43. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puo-polo M, and others. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104.
44. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, and others. 2003. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol 141:132-140.
45. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, and others. 2005. Longitudinal single-cell cyto-kine responses reveal recurrent autoimmune myelin reactivity in relapsing-remitting multiple sclerosis patients. Mult Scler 11:251-260.
46. Navikas V, Link H. 1996. Review: cytokines and the patho-genesis of multiple sclerosis. J Neurosci Res 45:322-333.
47. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. 1990. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40:971-975.
48. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, and others. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725.
49. Ouyang W, Kolls JK, Zheng Y. 2008. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454-467.
50. Panitch H, Miller A, Paty D, Weinshenker B. 2004. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788-1795.
51. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, and others. 1999. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53: 751-757.
52. Pender MP, Csurhes PA, Greer JM, Mowat PD, Henderson RD, Cameron KD, and others. 2000. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 165: 5322-5331.
53. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, and others. 2011. Th17 cells induce ectopic lym-phoid follicles in central nervous system tissue inflammation. Immunity 35:986-996.
54. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, and others. 2010. Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67:707-714.
55. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, and others. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910.
56. Prineas JW. 1979. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 203:1123-1125.
57. Ragheb S, Li Y, Simon K, VanHaerents S, Galimberti D, De Riz M, and others. 2011. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 17:819-829.
58. Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, and others. 2013. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 19:877-884.
59. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, and others. 1998. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50:1294-1300.
60. Sakai K, Namikawa T, Kunishita T, Yamanouchi K, Tabira T. 1986. Studies of experimental allergic encephalomy-elitis by using encephalitogenic T cell lines and clones in euthymic and athymic mice. J Immunol 137:1527-1531.
61. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, and others. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219.
62. Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, and others. 2009. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73:2003-2010.
63. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164-174.
64. Steinman L, Zamvil SS. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12-21.
65. Stüve O. 2008. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 274:39-41.
66. Trapp BD, Nave KA. 2008. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247-269.
67. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, and others. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146-155.
68. Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M. 2007. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0M gadolinium chelates for detecting multiple sclerosis lesions. AJR Am J Roent-genol 188:697-702.
69. Wang LM, Zhang DM, Xu YM, Sun SL. 2011. Interleukin 2 receptor a gene polymorphism and risk of multiple sclerosis: a meta-analysis. J Int Med Res 39:1625-1635.
70. Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, and others. 2001. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 112:139-145.
71. Weiner HL. 2008. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 255 Suppl 1:3-11.
72. Zuvich RL, McCauley JL, Oksenberg JR, Sawcer SJ, De Jager PL, Aubin C, and others. 2010. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 127:525-535.